Abstract
The high infectivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the lack of preexisting immunity among the population, and the complexity of the coronavirus disease 2019 (COVID-19) clinical presentation are some of the underlying reasons of the ongoing worldwide health crisis. Antibodies play relevant roles in antiviral responses,1 and hence, patients with compromised specific humoral immunity may be at increased risk to suffer from severe forms of the disease. In fact, 3 recent studies described the clinical evolution of 6 patients with common variable immunodeficiency (CVID), 3 patients with x-linked agammagloblulinemia (XLA) (OMIM# 300755; Bruton's disease), and 1 patient with autosomal agammaglobulinemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
